Genistein inhibits the S‑phase kinase‑associated protein 2 expression in breast cancer cells

Ye,Dengfeng; Li,Zhian; Wei,Chunshou

doi:10.3892/etm.2017.5489

Genistein inhibits the S‑phase kinase‑associated protein 2 expression in breast cancer cells

Authors:
- Dengfeng Ye
- Zhian Li
- Chunshou Wei
View Affiliations

Affiliations: Department of Oncological Surgery, The Second Hospital of Shaoxing, Shaoxing, Zhejiang 312000, P.R. China
Published online on: November 10, 2017 https://doi.org/10.3892/etm.2017.5489
Pages: 1069-1075
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most lethal cancers affecting women worldwide and was estimated to account for ~30% of all new cancer diagnoses in women. Although available evidence has proved the tumor suppressor role of genistein in cancer, the underling mechanisms have remained to be fully elucidated. S‑phase kinase‑associated protein 2 (Skp2) has been revealed to critically enhance the pathogenesis of multiple human cancers. The present study determined whether genistein exerts its anti‑tumor function by suppressing Skp2 in breast cancer cells. Genistein significantly inhibited the proliferation, invasion and migration of breast cancer cells. Furthermore, genistein treatment also induced marked apoptosis and a typical cell cycle arrest in G2/M phase. Mechanistically, genistein treatment was identified to cause a significant downregulation of Skp2. Two crucial tumor suppressors, p21 and p27, were upregulated in genistein‑treated breast cancer cells. The present results revealed that genistein exerted its tumor suppressor effect at least partially via inhibition of Skp2 and promotion of its downstream targets p21 and p27. Therefore, inactivation of Skp2 by genistein may be a promising approach for breast cancer treatment.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, Ju X, Ojeifo J, Jiao X, Yeow WS, Katiyar S, et al: The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 70:10464–10473. 2010. View Article : Google Scholar : PubMed/NCBI
3	He M, Fu Y, Yan Y, Xiao Q, Wu H, Yao W, Zhao H, Zhao L, Jiang Q, Yu Z, et al: The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. Clin Sci (Lond). 129:809–822. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ibrahim SA, Gadalla R, El-Ghonaimy EA, Samir O, Mohamed HT, Hassan H, Greve B, El-Shinawi M, Mohamed MM and Götte M: Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer. 16:572017. View Article : Google Scholar : PubMed/NCBI
5	Jang GB, Kim JY, Cho SD, Park KS, Jung JY, Lee HY, Hong IS and Nam JS: Blockade of Wnt/b-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci Rep. 5:124652015. View Article : Google Scholar : PubMed/NCBI
6	Wang G, Chan CH, Gao Y and Lin HK: Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression and metastasis. Chin J Cancer. 31:169–177. 2012. View Article : Google Scholar : PubMed/NCBI
7	Frescas D and Pagano M: Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the scales of cancer. Nat Rev Cancer. 8:438–449. 2008. View Article : Google Scholar : PubMed/NCBI
8	Wang Z, Liu P, Inuzuka H and Wei W: Roles of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014. View Article : Google Scholar : PubMed/NCBI
9	Chan CH, Morrow JK, Zhang S and Lin HK: Skp2: A dream target in the coming age of cancer therapy. Cell Cycle. 13:679–680. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhang W, Cao L, Sun Z, Xu J, Tang L, Chen W, Luo J, Yang F, Wang Y and Guan X: Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation. Cell Cycle. 15:1344–1351. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yang C, Nan H, Ma J, Jiang L, Guo Q, Han L, Zhang Y, Nan K and Guo H: High Skp2/Low p57(Kip2) expression is associated with poor prognosis in human breast carcinoma. Breast Cancer (Auckl). 9 Suppl 1:S13–S21. 2015.
12	Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH and Wei W: Skp2 is a promising therapeutic target in breast cancer. Front Oncol. 1:2012. View Article : Google Scholar : PubMed/NCBI
13	Messina M, Nagata C and Wu AH: Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer. 55:1–12. 2006. View Article : Google Scholar : PubMed/NCBI
14	Pavese JM, Farmer RL and Bergan RC: Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev. 29:465–482. 2010. View Article : Google Scholar : PubMed/NCBI
15	Choi YH, Zhang L, Lee WH and Park KY: Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol. 13:391–396. 1998.PubMed/NCBI
16	Valachovicova T, Slivova V, Bergman H, Shuherk J and Sliva D: Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways. Int J Oncol. 25:1389–1395. 2004.PubMed/NCBI
17	Li Y, Chen H, Hardy TM and Tollefsbol TO: Epigenetic regulation of multiple tumor-related genes leads to suppression of breast tumorigenesis by dietary genistein. PLoS One. 8:e543692013. View Article : Google Scholar : PubMed/NCBI
18	Bonofiglio D, Giordano C, De Amicis F, Lanzino M and Andò S: Natural products as promising antitumoral agents in breast cancer: Mechanisms of action and molecular targets. Mini Rev Med Chem. 16:596–604. 2016. View Article : Google Scholar : PubMed/NCBI
19	Nagata C, Mizoue T, Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Wakai K, Inoue M, Tsugane S, Sasazuki S, et al: Soy intake and breast cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 44:282–295. 2014. View Article : Google Scholar : PubMed/NCBI
20	Uifalean A, Schneider S, Ionescu C, Lalk M and Iuga CA: Soy Isoflavones and breast cancer cell lines: Molecular mechanisms and future perspectives. Molecules. 21:E132015. View Article : Google Scholar : PubMed/NCBI
21	Sarkar FH and Li Y: Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev. 21:265–280. 2002. View Article : Google Scholar : PubMed/NCBI
22	Wang TT, Sathyamoorthy N and Phang JM: Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis. 17:271–275. 1996. View Article : Google Scholar : PubMed/NCBI
23	Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 262:5592–5595. 1987.PubMed/NCBI
24	Corbett AH, Hong D and Osheroff N: Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. J Biol Chem. 268:14394–14398. 1993.PubMed/NCBI
25	Shafiee G, Saidijam M, Tavilani H, Ghasemkhani N and Khodadadi I: Genistein induces apoptosis and inhibits proliferation of HT29 colon cancer cells. Int J Mol Cell Med. 5:178–191. 2016.PubMed/NCBI
26	Wang SD, Chen BC, Kao ST, Liu CJ and Yeh CC: Genistein inhibits tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. BMC Complement Altern Med. 14:262014. View Article : Google Scholar : PubMed/NCBI
27	Zhao Q, Zhao M, Parris AB, Xing Y and Yang X: Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells. Int J Oncol. 49:1203–1210. 2016. View Article : Google Scholar : PubMed/NCBI
28	Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, et al: Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 111:4690–4699. 2008. View Article : Google Scholar : PubMed/NCBI
29	Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, et al: Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 154:556–568. 2013. View Article : Google Scholar : PubMed/NCBI
30	Jandial DD, Krill LS, Chen L, Wu C, Ke Y, Xie J, Hoang BH and Zi X: Induction of G2M arrest by flavokawain A, a kava chalcone, increases the responsiveness of her2-overexpressing breast cancer cells to herceptin. Molecules. 22:2017. View Article : Google Scholar : PubMed/NCBI
31	Huang C, Wei YX, Shen MC, Tu YH, Wang CC and Huang HC: Chrysin, abundant in morinda citrifolia fruit water-etoac extracts, combined with apigenin synergistically induced apoptosis and inhibited migration in human breast and liver cancer cells. J Agric Food Chem. 64:4235–4245. 2016. View Article : Google Scholar : PubMed/NCBI
32	Su J, Zhou X, Wang L, Yin X and Wang Z: Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells. Am J Cancer Res. 6:1949–1962. 2016.PubMed/NCBI
33	Feng S, Wang Y, Zhang R, Yang G, Liang Z, Wang Z and Zhang G: Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells. Onco Targets Ther. 10:2377–2388. 2017. View Article : Google Scholar : PubMed/NCBI
34	Huang MH, Lin SZ, Lin PC, Chiou TW, Harn YW, Ho LI, Chan TM, Chou CW, Chuang CH, Su HL and Harn HJ: Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability. Tumour Biol. 35:4875–4884. 2014. View Article : Google Scholar : PubMed/NCBI
35	Yin X, Zhang Y, Su J, Hou Y, Wang L, Ye X, Zhao Z, Zhou X, Li Y and Wang Z: Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells. Oncotarget. 7:66512–66524. 2016. View Article : Google Scholar : PubMed/NCBI
36	Su J, Wang L, Yin X, Zhao Z, Hou Y, Ye X, Zhou X and Wang Z: Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells. Am J Cancer Res. 6:2178–2191. 2016.PubMed/NCBI